Welcome to our dedicated page for Waters SEC filings (Ticker: WAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Waters Corporation filings document operating results, proxy governance, capital-structure changes, material agreements, and corporate events for a NYSE-listed life sciences and diagnostics company. Recent 8-K reports include quarterly and annual results, exhibits furnished with earnings releases, and disclosure tied to the completed combination with BD’s Biosciences and Diagnostic Solutions business.
The company’s SEC record also covers senior unsecured notes issued by Augusta SpinCo Corporation and guaranteed by Waters and certain subsidiaries, pro forma and combined financial information for the acquired business, and definitive proxy materials addressing board oversight, shareholder voting matters, executive compensation, and governance practices.
Heather Knight, a Director of Waters Corp (WAT), reported a Form 4 disclosing receipt of 77.88 common stock units on 09/30/2025 under the Issuer's 1996 Non-Employee Director Deferred Compensation Plan. The filing states these common stock units were received in lieu of cash director fees and are convertible one-for-one into shares of the company's common stock upon distribution, which the reporting person elected to occur on 01/01/2027. After the reported transaction the form shows 759.28 shares beneficially owned by the reporting person. The Form 4 was signed by attorney-in-fact Michael Lynn on 10/02/2025.
The reporting person, Wei Jiang, a director of Waters Corp (WAT), received 72.91 common stock units on 09/30/2025 in lieu of cash director fees under the issuer's 1996 Non-Employee Director Deferred Compensation Plan. Those units convert one-for-one into shares on distribution, and the reporting person elected to have distributions occur on January 1, 2035. Following the transaction the reporting person beneficially owns 2,551.48 shares (or equivalent units). The units were reported as acquired at a price of $0 and were signed on behalf of the reporting person by an attorney-in-fact.
Waters Corp. (WAT) Q2 2025 10-Q highlights
- Net sales: $771.3 m, up 8.9 % YoY; YTD $1.43 bn, +6.5 %.
- Mix: Product $473.4 m (+8.8 %), Service $297.9 m (+9.0 %).
- Profitability: Q2 operating income $188.2 m (24.4 % margin vs 26.7 %), essentially flat YoY. Net income $147.1 m (+3 %); diluted EPS $2.47 (vs $2.40). YTD EPS $4.50 (+9.2 %).
- Cash & debt: Cash $367 m (↑$42 m YTD); total debt $1.46 bn (↓$169 m). Current $260 m of notes re-classified as short-term; amended credit facility now $1.8 bn maturing 2030.
- Working capital: Inventories $541 m (+13 % since FY-end); A/R flat; deferred revenue up $113 m to $420 m.
- Cash flow: Operating cash flow $300.7 m (-5 % YoY); capex & software $48 m; free cash flow ~$253 m. Share buybacks limited to $14 m for RSU tax withholding.
- Acquisitions & strategy: Closed May 2025 purchase of Halo Labs for $35 m (adds particle-analysis tech). Subsequent event: definitive agreement (13 Jul 25) to acquire BD Biosciences & Diagnostic Solutions for ~$17.5 bn cash/stock—transformative if completed.
- Guidance: none provided; management notes FX headwinds, ERP roll-out ($130 m over 3 yrs) and higher tax rate (17.2 % vs 15.7 %).
- Balance-sheet strength: Equity $2.16 bn vs $1.83 bn FY-end; leverage (net debt/EBITDA) falls to ~2.7× pre-BD deal.
Overall, Waters delivered mid-single-digit growth and steady EPS, while preparing for a large, leverage-adding acquisition that could significantly reshape its scale and risk profile.
Waters Corporation (NYSE: WAT) filed an 8-K dated 4-Aug-2025. Under Item 2.02 the Company furnished, but did not file, a press release (Exhibit 99.1) detailing results for the quarter ended 28-Jun-2025; the actual revenue, EPS and margin figures are not included in the text of this report.
The filing also discloses preparations for a multi-step transaction involving Waters, Augusta SpinCo Corporation and Becton, Dickinson and Company. The parties plan to submit a Form S-4 (proxy/prospectus) and a Form 10 (information statement) to the SEC in connection with a spin-off of SpinCo from BD and its subsequent combination with Waters. Investors are urged to review those future documents when available.
No pro-forma financials, valuation terms, timing or regulatory approvals are provided at this stage. Apart from standard safe-harbor language and emerging-growth-company check-boxes, the only other material content is the exhibit list (99.1 press release; 104 Inline XBRL cover).
Waters Corporation (NYSE: WAT) filed an 8-K to disclose a material strategic transaction. The company has signed an agreement to combine Becton, Dickinson & Company’s (BD) Biosciences and Diagnostics Solutions business with Waters (the “Proposed Transaction”). No financial terms, deal value, or pro-forma forecasts were provided in the filing.
Key highlights
- Transaction scope: The combination would add BD’s Biosciences and Diagnostics Solutions unit to Waters’ existing analytical-instrument franchise, potentially expanding Waters’ end-market exposure from life-science research into clinical diagnostics.
- Communication timeline: A joint conference call and webcast was scheduled for 8:00 a.m. ET on 14 July 2025. The related press release (Ex. 99.1) and investor presentation (Ex. 99.2) are furnished—but not filed—under Regulation FD.
- Regulatory & shareholder approvals: Completion is subject to customary closing conditions, including Waters shareholder approval and multiple regulatory clearances.
- Forward-looking statements & risks: Waters lists 17 specific risk factors that could cause the deal to fail or the combined company to under-perform. Prominent risks include antitrust hurdles, integration complexity, cost overruns, talent retention, tax treatment, and potential litigation.
Accounting treatment: Because the information is furnished under Item 7.01 (Regulation FD) rather than 1.01 (Entry into a Material Definitive Agreement), it is not deemed “filed” for Section 18 liability.
Take-away: The announcement signals Waters’ intent to accelerate growth through a transformative acquisition, but material uncertainties remain until financial terms, financing structure, and regulatory feedback are disclosed.
Waters Corp. (NYSE: WAT) has filed a Form 4 indicating that director Wei Jiang acquired 68.35 common-stock units on 30 June 2025. The units were issued at a stated price of $0.00 because they represent deferred, stock-settled compensation in lieu of cash director fees under the company’s 1996 Non-Employee Director Deferred Compensation Plan. Each unit converts into one share of common stock on 1 January 2035, in line with the reporting person’s prior deferral election. Following the issuance, Jiang’s direct beneficial ownership rises to 2,478.57 shares. No derivative securities were bought or sold, and no shares were disposed of. The filing reflects a routine, low-dollar insider acquisition that marginally increases director equity alignment but is not material to Waters’ overall share count or valuation.
Waters Corp (WAT) filed a Form 4 on 26 June 2025 for insider Robert L. Carpio III, Senior Vice President of the Waters Division. On 24 June 2025, the company withheld 134 shares of common stock (transaction code F) at $346.80 per share to cover tax obligations associated with the vesting of previously granted restricted stock units. The withholding represents an estimated tax value of roughly $46.5 thousand. Following the transaction, Carpio directly owns 2,656 shares of WAT. No open-market trading or derivative activity was reported, indicating the event is administrative rather than strategic.